Methods for Establishing a Renal Cell Carcinoma Tumor Spheroid Model With Immune Infiltration for Immunotherapeutic Studies.

PD-1 heterogeneity immune checkpoint inhibitors personalized medicine renal cell carcinoma spheroid standardization

Journal

Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867

Informations de publication

Date de publication:
2022
Historique:
received: 17 03 2022
accepted: 01 06 2022
entrez: 15 8 2022
pubmed: 16 8 2022
medline: 16 8 2022
Statut: epublish

Résumé

Tumor spheroids play an increasingly important role in cancer research. Their ability to recapitulate crucial features of tumor biology that are lost in the classically used 2D models along with their relative simplicity and handiness have made them the most studied 3D tumor model. Their application as a theranostic tool or as a means to study tumor-host interaction is now well-established in various cancers. However, their use in the field of Renal Cell Carcinoma (RCC) remains very limited. The aim of this work is to present methods to implement a basic RCC spheroid model. These methods cover the steps from RCC tumor dissociation to spheroid infiltration by immune cells. We present a protocol for RCC dissociation using Liberase TM and introduce a culture medium containing Epithelial Growth Factor and Hydrocortisone allowing for faster growth of RCC primary cells. We show that the liquid overlay technique allows for the formation of spheroids from cell lines and from primary cultures. We present a method using morphological criteria to select a homogeneous spheroid population based on a Fiji macro. We then show that spheroids can be infiltrated by PBMCs after activation with OKT3 or IL-15. Finally, we provide an example of application by implementing an immune spheroid killing assay allowing observing increased spheroid destruction after treatment with PD-1 inhibitors. Thus the straightforward methods presented here allow for efficient spheroid formation for a simple RCC 3D model that can be standardized and infused with immune cells to study immunotherapies.

Identifiants

pubmed: 35965544
doi: 10.3389/fonc.2022.898732
pmc: PMC9366089
doi:

Types de publication

Journal Article

Langues

eng

Pagination

898732

Informations de copyright

Copyright © 2022 Lugand, Mestrallet, Laboureur, Dumont, Bouhidel, Djouadou, Masson-Lecomte, Desgrandchamps, Culine, Carosella, Rouas-Freiss and LeMaoult.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Références

Cytotherapy. 2011 Sep;13(8):1000-12
pubmed: 21619419
Sci Data. 2017 Nov 21;4:170170
pubmed: 29160867
Front Mol Biosci. 2020 Mar 06;7:33
pubmed: 32211418
Cancers (Basel). 2021 May 22;13(11):
pubmed: 34067456
Curr Opin Oncol. 2019 May;31(3):194-199
pubmed: 30985497
Sci Rep. 2016 Jan 11;6:19103
pubmed: 26752500
Nat Methods. 2012 Jun 28;9(7):676-82
pubmed: 22743772
Oncoimmunology. 2017 Jul 5;6(9):e1342023
pubmed: 28932645
Clin Exp Immunol. 2021 Apr;204(1):96-106
pubmed: 33346915
Front Immunol. 2015 Oct 12;6:500
pubmed: 26528284
J Craniofac Surg. 2016 Jan;27(1):222-8
pubmed: 26703050
Cells. 2021 Jun 08;10(6):
pubmed: 34201301
Cancer Immunol Res. 2017 Nov;5(11):950-956
pubmed: 28963140
Cancer Med. 2016 Jul;5(7):1444-53
pubmed: 27073068
Hum Immunol. 1999 Dec;60(12):1303-9
pubmed: 10626746
Cancer Immunol Immunother. 2017 Jan;66(1):129-140
pubmed: 27858101
Cancers (Basel). 2020 Jan 17;12(1):
pubmed: 31963500
BMC Biol. 2012 Mar 22;10:29
pubmed: 22439642
Eur Cytokine Netw. 2005 Jun;16(2):123-7
pubmed: 15941683
Front Immunol. 2020 Oct 02;11:02168
pubmed: 33123122
J Immunother Cancer. 2019 Mar 14;7(1):74
pubmed: 30871626
Biotechnol Adv. 2016 Dec;34(8):1427-1441
pubmed: 27845258
Diabetes. 1997 Jul;46(7):1120-3
pubmed: 9200645
Biomedicines. 2021 Mar 15;9(3):
pubmed: 33804204
Sci Rep. 2019 Feb 14;9(1):2133
pubmed: 30765891
ESMO Open. 2019 Aug 19;4(4):e000536
pubmed: 31555484
Hum Reprod. 2006 Feb;21(2):413-20
pubmed: 16199426
Mol Cancer. 2016 Dec 19;15(1):83
pubmed: 27993170
Int J Cancer. 2005 Oct 20;117(1):114-22
pubmed: 15880415
Cancer Res. 2020 Jan 15;80(2):263-275
pubmed: 31744818
Methods Mol Biol. 2019;1930:75-82
pubmed: 30610601
Cancer Discov. 2018 Feb;8(2):196-215
pubmed: 29101162
J Clin Invest. 2017 Mar 1;127(3):801-813
pubmed: 28134623
Ann Anat. 2018 Mar;216:1-8
pubmed: 29162481

Auteurs

Leonard Lugand (L)

Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France.

Guillaume Mestrallet (G)

Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France.

Rebecca Laboureur (R)

Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France.

Clement Dumont (C)

Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France.
Department of Medical Oncology, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France.

Fatiha Bouhidel (F)

Service d'Anatomopathologie Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Laboratory of Pathology, UMR-S728, Paris, France.

Malika Djouadou (M)

Department of Urology, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France.

Alexandra Masson-Lecomte (A)

Department of Urology, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France.

Francois Desgrandchamps (F)

Department of Urology, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France.

Stephane Culine (S)

Department of Medical Oncology, Saint-Louis Hospital, AP-HP.Nord - Université de Paris, Paris, France.

Edgardo D Carosella (ED)

Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France.

Nathalie Rouas-Freiss (N)

Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France.

Joel LeMaoult (J)

Hemato-Immunology Research Department, CEA, DRF-Francois Jacob Institute, Saint-Louis Hospital, Paris, France - U976 HIPI Unit, IRSL, Paris University, Paris, France.

Classifications MeSH